Evotec (EVT) PT Set at €16.00 by Berenberg Bank
Evotec (ETR:EVT) has been given a €16.00 ($19.05) target price by investment analysts at Berenberg Bank in a report issued on Thursday. The brokerage presently has a “neutral” rating on the stock. Berenberg Bank’s price objective points to a potential upside of 34.57% from the stock’s current price.
Other equities research analysts have also issued research reports about the company. Oddo Securities set a €14.00 ($16.67) price objective on Evotec and gave the stock a “neutral” rating in a research report on Friday, August 11th. Deutsche Bank set a €16.00 ($19.05) price objective on Evotec and gave the stock a “neutral” rating in a research report on Wednesday, August 30th. Finally, Oddo Bhf set a €20.00 ($23.81) price objective on Evotec and gave the stock a “buy” rating in a research report on Wednesday, November 29th.
Evotec (ETR EVT) traded up €0.29 ($0.35) during trading hours on Thursday, reaching €11.89 ($14.15). 1,418,071 shares of the company’s stock were exchanged, compared to its average volume of 3,200,000. Evotec has a 1-year low of €6.05 ($7.20) and a 1-year high of €22.50 ($26.79).
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.